Deep vein thrombosis in Ethiopia: a systematic review and meta-analysis, 2025

Deep Vein Thrombosis is a significant public health concern associated with high morbidity and mortality, mainly when left undiagnosed or untreated. In Ethiopia, fragmented data from various studies have reported varying prevalence and risk factors, necessitating a comprehensive synthesis. This systematic review aimed to identify and summarize the key factors contributing to deep vein thrombosis among patients in Ethiopia. The study used a systematic review and meta-analysis design, sourcing evidence from various electronic databases until April 04, 2025. Data was extracted from March 10-15 and analyzed from March 15-25, with the report generation until April 04, 2025. The mortality rate was assessed using the pooled odds ratio and the pooled proportion. A meta-analysis was conducted using R software, with forest plots for visual representation. Heterogeneity was evaluated using the I² statistic. The quality of the studies was assessed using validated tools. The review showed the pooled prevalence of deep vein thrombosis from eight articles was 5.6%( CI: 2.9, 8.5), with a 5% mortality rate (CI: 3, 8), and a 7.15%( CI: 2, 12) recurrence rate. Advanced age, being male, pregnancy, hypertension, diabetes, comorbid conditions, and a history of Deep Vein Thrombosis, high cholesterol level, orthopedic trauma, Alcohol consumption, and obesity, Patients with bilateral Deep Vein Thrombosis prolonged hospitalization, ward admission, and patient transfer from other hospitals, and use of central venous catheters were associate with increased the risk of Deep Vein Thrombosis development. The review showed that Deep Vein Thrombosis is a significant health concern in Ethiopia, with a prevalence of 5.6%, a mortality rate of 5%, and a recurrence rate of 7.15%. Factors such as advanced age, pregnancy, prior deep-vein thrombosis, comorbidities, intensive care unit admission, surgery, prolonged hospitalization, and central venous catheter use increase risk. To reduce DVT-related complications, routine risk assessments, early intervention strategies, and strengthened hospital protocols are essential. CRD420251024491 was registered with PROSPERO on 06 April 2025.